Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Inhaled BGF 160 on Tidal Breathing Complexity in Stable COPD
2024-514097-52-00Phase 4Authorised
- Sponsor
- CHU de Lille
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide in chronic obstructive pulmonary disease (COPD), sponsored by CHU de Lille. Planned start Dec 2024; status: authorised.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-514097-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514097-52-00.